Japan: Joint R&D with the Goal of Commercialization of a Scaled-Down, Methylated DNA Detection Device for Renal Cell Carcinoma Prognostication, and Other Cancers, by 2018May 04, 2015
National Cancer Center Japan, in conjunction with Sekisui Medical Co., Ltd. has undertaken research into the prognostication of Renal Cell Carcinoma, and the commercialization of a scaled-down methylated DNA detection device. With a view to commercialization by 2018, the joint research program is now proceeding with R&D into non-RCC diagnosis devices.
The current research results into RCC prognostication were accomplished by the National Cancer Center on behalf of the National Institute of Biomedical, under the Promotion of Fundamental Studies in Health Sciences. Dr. Yae Kanai published these results in the cancer journal BMC Cancer.
Please find the full press release here: crest-ihec.jp/english/results/index.html